[1]商红叶,杨 茂,郭 卉.薏苡仁三酰甘油联合化疗栓塞对中晚期肝癌患者免疫功能的影响[J].介入放射学杂志,2015,(09):807-810.
 SHANG Hong- ye,YANG Mao,GUO Hui.Influence of coix seed triglyceride combined with transcatheter arterial chemoembolization therapy on the immune function in patients with advanced primary hepatocellular carcinoma[J].journal interventional radiology,2015,(09):807-810.
点击复制

薏苡仁三酰甘油联合化疗栓塞对中晚期肝癌患者免疫功能的影响 ()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2015年09期
页码:
807-810
栏目:
临床研究
出版日期:
2015-09-25

文章信息/Info

Title:
Influence of coix seed triglyceride combined with transcatheter arterial chemoembolization therapy on the immune function in patients with advanced primary hepatocellular carcinoma
作者:
商红叶 杨 茂 郭 卉
Author(s):
SHANG Hong- ye YANG Mao GUO Hui
Department of Hepatobiliary Diseases, First Affiliated Hospital, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
关键词:
【关键词】 原发性肝细胞癌 往动脉注入栓塞 薏苡仁三酰甘油 T淋巴细胞亚群 CD4+CD25+调节T细胞(Treg细胞)
文献标志码:
A
摘要:
【摘要】 目的 分析薏苡仁三酰甘油联合肝动脉化疗栓塞(TACE)对中晚期原发性肝癌(HCC)患者AFP、CD4+CD25+调节T(Treg)细胞、细胞免疫功能的影响及临床意义。方法 回顾50例中晚期HCC患者(经影像学检查显示无远处转移)资料,依据治疗方式分为两组:薏苡仁三酰甘油联合TACE治疗25例为研究组,单纯TACE治疗25例为对照组,研究组患者在TACE同时经肝动脉灌注薏苡仁三酰甘油100 ml,术后应用薏苡仁三酰甘油静滴5 d,每日200 ml。分别于治疗前1周、治疗后1个月取外周血,检测AFP、T淋巴细胞亚群(CD3+、CD4+、 CD8+ 、CD4+/CD8+、 Treg)水平变化;术后1个月采用增强CT、MRI或PET- CT评价肿瘤坏死程度。结果 两组治疗后AFP均下降,差异具有统计学意义(P<0.01),研究组肿瘤坏死率(57.7±8.2)%较对照组(56.8±8.5)%略高,但差异无统计学意义(P>0.05)。研究组Treg细胞比例由(8.27±6.65)%下降至(4.22±1.59)%,二者差异具有统计学意义(P<0.01);CD3+、CD4+细胞比例及CD4+/CD8+分别由(55.78±13.66)%、(43.98±14.00)%、1.22±0.64上升至(62.29±10.78)%(P<0.01)、(51.82±16.32)%(P<0.05)、1.54±0.80(P<0.05),CD8+由(45.71±12.94)%下降至(39.70±12.41)%(P<0.05)。对照组治疗前后比较差异均无统计学意义(P>0.05)。结论 薏苡仁三酰甘油联合TACE治疗中晚期肝癌可以降低Treg细胞比例,可能在一定程度上影响患者细胞免疫状态,有可能降低HCC患者TACE术后复发的机会。

参考文献/References:

[参 考 文 献]
[1] Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61: 69- 90.
[2] Maluccio M, Covey A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma[J]. CA Cancer J Clin, 2012, 62: 394- 399.
[3] Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008[J]. J Hepatol, 2008, 48: S20- S37.
[4] 许 锋, 谢 敏, 包善华, 等. 康莱特注射液对胰腺癌手术和介入化疗后免疫功能的评价[J]. 中华临床医师杂志?电子版, 2012, 6: 132- 134.
[5] 杨晓玲. 康莱特注射液对晚期恶性肿瘤患者生活质量及免疫功能影响的临床观察[J]. 山西中医, 2013, 29: 20- 21.
[6] Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival[J]. Hepatology, 2003, 37: 429- 442.
[7] 刘 松, 孟冉冉, 张跃伟. 经肝动脉化疗栓塞与树突状细胞治疗肝癌对机体免疫功能的影响[J]. 介入放射学杂志, 2014, 23: 181- 184.
[8] 包三裕, 张 洪. 康莱特注射液作用机理及临床应用研究[J]. 长春中医药大学学报, 2011, 27: 139- 140.
[9] 韩聚强, 范公忍, 任永强, 等. 不同微创介入治疗原发性肝癌对机体T细胞免疫功能的影响[J]. 介入放射学杂志, 2014, 23: 218- 221.
[10] 姚庆华, 郭 勇. 薏苡仁甘油三酯(康莱特)治疗晚期恶性肿瘤患者机制研究进展[J]. 中国肿瘤临床, 2012, 39: 1151- 1154.
[11] 武晋荣, 赵和平. 康莱特对小鼠肝癌细胞Hepa1- 6增殖和凋亡的影响[J]. 中国医药导报, 2010, 7: 18- 20.
[12] 郭 志, 邢文阁, 刘 方, 等. 氩氦冷冻在原发巨块型肝癌介入治疗中的临床应用[J]. 中华放射学杂志, 2005, 39: 198- 203.
[13] Ladhams A, Schmidt C, Sing G, et al. Treatment of non- resectable hepatocellular carcinoma with autologous tumor- pulsed dendritic cells[J]. J Gastroenterol Hepatol, 2002, 17: 889- 896.
[14] Shimizu J, Yamazaki S, Takahashi T, et al. Stimulation of CD25+CD4+regulatory T cells through GITR breaks immunological self- tolerance[J]. Nat Immunol, 2002, 3: 135- 142.
[15] Ormandy LA, Hillemann T, Wedemeyer H, et al. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma[J]. Cancer Res, 2005, 65: 2457- 2464.
[16] Kobayashi N, Hiraoka N, Yamagami W, et al. FOXP3+ regulatory T cells affect the development and progression of hepatocar- cinogenesis[J]. Clin Cancer Res, 2007, 13: 902- 911.
[17] Imai H, Saio M, Nonaka K, et al. Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma[J]. Cancer Sci, 2007, 98: 416- 423.

相似文献/References:

[1]孙世蒙,郭应兴,雷振武,等.TACE治疗原发性肝癌伴门静脉癌栓研究进展 [J].介入放射学杂志,2017,(07):668.
 SUN Shimeng,GUO Yingxing,LEI Zhenwu,et al.TACE for the treatment of primary hepatocellular carcinoma associated with portal vein tumor thrombus: recent progress in research[J].journal interventional radiology,2017,(09):668.
[2]崔 鹏,杜小丽,周 瀚,等.TACE治疗肝癌伴门脉癌栓患者的预后分析 [J].介入放射学杂志,2018,27(03):266.
 CUI Peng,DU Xiaoli,ZHOU Han,et al.Transcatheter arterial chemoembolization for hepatocellular carcinoma complicated by portal vein tumor thrombosis: prognostic analysis[J].journal interventional radiology,2018,27(09):266.

备注/Memo

备注/Memo:
(收稿日期:2014-12-24)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2015-09-23